944401-60-9

Usage

Uses

Used in Pharmaceutical Industry:
4-chloro-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-amine is used as a synthetic intermediate for the development of various drugs and pharmaceutical products. Its unique structure, including a chlorine atom and a boron-containing group, allows for versatile reactions and functionalization in organic synthesis, facilitating the creation of new therapeutic agents.
Used in Organic Synthesis:
In the field of organic synthesis, 4-chloro-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-amine is used as a building block for the development of novel compounds and materials. The presence of the boron-containing group makes it particularly useful for cross-coupling and functionalization reactions, enabling the synthesis of a wide range of organic compounds with potential applications in various industries.
Used in Medicine:
4-chloro-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-amine is utilized in the medical field as a key component in the synthesis of pharmaceuticals. Its reactivity and structural features make it a valuable asset in the development of new drugs and therapeutic agents, contributing to advancements in medical treatments and healthcare.
Used in Agriculture:
In agriculture, 4-chloro-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-amine is employed in the synthesis of agrochemicals and pesticides. Its versatility in organic reactions allows for the development of new compounds with potential applications in crop protection and pest control, enhancing agricultural productivity and sustainability.
Used in Materials Science:
4-chloro-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-amine is also used in materials science for the synthesis of new materials with specific properties. Its involvement in the development of novel compounds and materials can lead to innovations in various applications, such as sensors, catalysts, and advanced materials for industrial use.

Upstream product

• 942947-94-6 5-bromo-4-chloro-pyridin-2-ylamine 
• 73183-34-3 bis(pinacol)diborane 

Relevant academic research and scientific papers

METHOD OF INHIBITING HAMARTOMA TUMOR CELLS

Dimorpholinopyrimidines are useful for inhibiting growth or proliferation of hamartoma tumor cells. Because the Dimorpholinopyrimidines inhibit the growth and proliferation of hamartoma tumor cells they are also useful in treating PTEN hamartoma tumor syndromes. The therapeutic and prophylactic treatments provided by this invention are practiced by administering to a patient in need thereof an amount of a compound of dimorpholinopyrimidine derivative that is effective to inhibit growth or proliferation of the hamartoma tumor cells.

Identification of NVP-BKM120 as a potent, selective, orally bioavailable class i PI3 kinase inhibitor for treating cancer

Phosphoinositide-3-kinases (PI3Ks) are important oncology targets due to the deregulation of this signaling pathway in a wide variety of human cancers. Herein we describe the structure guided optimization of a series of 2-morpholino, 4-substituted, 6-heterocyclic pyrimidines where the pharmacokinetic properties were improved by modulating the electronics of the 6-position heterocycle, and the overall druglike properties were fine-tuned further by modification of the 4-position substituent. The resulting 2,4-bismorpholino 6-heterocyclic pyrimidines are potent class I PI3K inhibitors showing mechanism modulation in PI3K dependent cell lines and in vivo efficacy in tumor xenograft models with PI3K pathway deregulation (A2780 ovarian and U87MG glioma). These efforts culminated in the discovery of 15 (NVP-BKM120), currently in Phase II clinical trials for the treatment of cancer.

PYRIMIDINE DERIVATIVES USED AS PI-3 KINASE INHIBITORS

Phosphatidylinositol (PI) 3-kinase inhibitor compounds (I), their pharmaceutically acceptable salts, and prodrugs thereof ; compositions of the new compounds, either alone or in combination with at least one additional therapeutic agent, with a pharmaceutically acceptable carrier; and uses of the new compounds, either alone or in combination with at least one additional therapeutic agent, in the prophylaxis or treatment of proliferative diseases characterized by the abnormal activity of growth factors, protein serine/threonine kinases, and phospholipid kinases.